- Price
- $2.00
- Day
- +2.04%
- Mkt Cap
- $238.18M
- 52W Range
- $1.30 – $2.79
- Volume
- 352.5K
- Beta
- 1.17
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc.
Read full article
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on Thursday, August 6, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast What: OmniAb conference.
Read full article